Reevaluation of the Bicycle Ergometry in the Diagnosis of Ischemic Heart Disease

Basheer Abdullah Marzoog; Peter Chomakhidze; Philipp Kopylov

doi:10.1101/2024.07.03.24309879

Abstract

Background Ischemic heart disease (IHD) and related complications and outcomes remain the most frequently reported cardiovascular events. However, the diagnosis and prevention of ischemic heart disease primary depends on the clinical manifestations and electrocardiography changes.

Objectives Patients with IHD are victims of the poor diagnostic methods and the prevention strategies.

Aims To assess the diagnostic accuracy of the used bicycle ergometry in the diagnosis of ischemic heart disease based on the results of the stress computed myocardial perfusion (CTP) imaging with vasodilator test (adenosine triphosphate).

Materials and methods A single center prospective, and non-randomized study included participations aged ≥ 40. The study included 38 participants with vs without IHD confirmed by CTP. The participants done bicycle ergometry following Bruce protocol then performed CTP. For statistical analysis used the descriptive statistics, Pearson Correlation test, Student test. The Statistica 12 program used for the statistical test.

Results The study included 38 participants included 19 (50 %) patients with positive stress induced myocardial perfusion defect on the CTP and 19 (50 %) with negative results. The mean age of the participants 58,77 years (std. div. ± 9,664). The bicycle ergometry specificity and sensitivity 61.11%, 57.89%, respectively. The diagnostic accuracy of the bicycle ergometry 59.46%.

Conclusions The bicycle ergometry test characterized by severe limitations in terms of the IHD diagnosis.

Others Recommended to combine additional diagnostic methods with the bicycle ergometry to improve it is diagnostic accuracy, such as single channel electrocardiography and exhaled breath analysis.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT06181799

Funding Statement

The work of Philipp Kopylov and Peter Chomakhidze was financed by the government assignment 1023022600020-6 'Application of mass spectrometry and exhaled air emission spectrometry for cardiovascular risk stratification'.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study approved by the Sechenov University, Russia, from 'Ethics Committee Requirement № 19-23 from 26.10.2023'.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes